Literature DB >> 29434371

Kidney cancer: PDL1 as a biomarker in high-risk RCC.

Rebecca Kelsey.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29434371     DOI: 10.1038/nrurol.2018.19

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.

Authors:  Daniel J George; Jean-François Martini; Michael Staehler; Robert J Motzer; Ahmed Magheli; Bernard Escudier; Paola Gerletti; Sherry Li; Michelle Casey; Brigitte Laguerre; Hardev S Pandha; Allan J Pantuck; Anup Patel; Maria J Lechuga; Alain Ravaud
Journal:  Clin Cancer Res       Date:  2018-01-26       Impact factor: 12.531

  1 in total
  3 in total

1.  Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.

Authors:  Lei Li; Xi Chen; Lu Hao; Qiuyan Chen; Haosheng Liu; Qing Zhou
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

2.  The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma.

Authors:  Zhixin Wang; Jiaqi Chen; Qianyu Li; Na Li; Jing Yu; Feng Liu
Journal:  J Oncol       Date:  2022-03-24       Impact factor: 4.375

3.  APOA1 mRNA and protein in kidney renal clear cell carcinoma correlate with the disease outcome.

Authors:  Wei Zeng; Guoguang Xiong; Li Hua; Yugang Hu; Xufeng Guo; Xiulan Peng
Journal:  Sci Rep       Date:  2022-07-20       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.